Bafna Pharmaceuticals Limited (BAFNAPH.NS) Stock Overview
Explore Bafna Pharmaceuticals Limited’s financial performance, market position, analyst ratings, and future outlook.
Bafna Pharmaceuticals Limited (BAFNAPH.NS)
Key Financials
Key Financials
Market Cap
4.6B
P/E Ratio
41.41
EPS (TTM)
$4.69
ROE
0.12%
BAFNAPH.NS Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Bafna Pharmaceuticals Limited (BAFNAPH.NS) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 86.24, suggesting the stock is in an overbought condition. Our forecasting models predict significant price movements, with a 12-month target of $131.15.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 41.41 and a market capitalization of 4.6B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.